Search

Anna Goc Phones & Addresses

  • San Jose, CA
  • Santa Clara, CA
  • Augusta, GA
  • Cleveland, OH

Publications

Us Patents

Pharmaceutical Micronutrient Composition And Its Use To Simultaneously Inhibit Multiple Cellular Mechanisms Of Infectivity Caused By Coronavirus, Its Variants And Mutants

View page
US Patent:
20210315857, Oct 14, 2021
Filed:
Mar 25, 2021
Appl. No.:
17/212727
Inventors:
MATTHIAS W. RATH - APTOS CA, US
MATTHIAS W. Rath - APTOS CA, US
Vadim O. Ivanov - CASTRO VALLEY CA, US
Anna Goc - Sanjose CA, US
International Classification:
A61K 31/352
A61K 31/375
A61K 31/198
A61K 31/05
A61K 36/31
A61K 31/12
A61K 31/7048
A61K 45/06
Abstract:
Pharmaceutical micronutrient composition including mixture D in this study helps to mitigate, inhibit, prevent and stop diseases caused by viral infections. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Additional micronutrients were tested with Mixture D and seemed to have beneficial effects.

Pharmaceutical Composition And Its Use To Inhibit Membrane Ace2 Expression

View page
US Patent:
20210315858, Oct 14, 2021
Filed:
Mar 9, 2021
Appl. No.:
17/196121
Inventors:
MATTHIAS W RATH - , US
MATTHIAS W Rath - APTOS CA, US
Vadim O Ivanov - CASTRO VALLEY CA, US
Anna Goc - Sanjose CA, US
International Classification:
A61K 31/375
A61K 31/353
A61K 33/30
A61K 31/201
A61K 36/484
A61P 31/14
Abstract:
The study shows that ascorbic acid and its combination with some natural compounds could be included in developing preventive and therapeutic approaches toward the current pandemic. Some natural compounds were effective in lowering ACE2 cellular expression, with the highest inhibitory effects observed for baicalin (75%) and theaflavin (50%). Significantly, combinations of these and other test compounds with ascorbic acid further decreased ACE2 expression. The highest impact of ascorbate on ACE2 expression was noted when combined with theaflavin (decrease from 50% to 87%), zinc aspartate (decrease from 22% to 62%), and with 10-undecenoic acid (from 18% to 53%). Our study provides valuable experimental confirmation of the efficacy of micronutrients in controlling ACE2 expression—the coronavirus cellular “entry” point. It further validates the importance of nutrient interactions in various aspects of cellular metabolism and in considering potential therapeutic applications of nutrient-based approaches.

Composition For Eye Health

View page
US Patent:
20190209489, Jul 11, 2019
Filed:
Jan 9, 2018
Appl. No.:
15/866450
Inventors:
Aleksandra Niedzwiecki - APTOS CA, US
Matthias W. Rath - APTOS CA, US
Anna Goc - SANJOSE CA, US
Waldemar Sumera - SANJOSE CA, US
International Classification:
A61K 31/07
A61K 31/375
A61K 31/355
A61K 31/198
A61K 31/385
A61K 31/047
A61K 31/01
A61K 36/28
A61K 36/15
A61K 36/87
A61K 36/45
A61K 33/30
A61P 27/02
Abstract:
The nutrient mixture made up of vitamin, carotenoid, micronutrient, essential trace element, and plant extract was much more effective in proactively protecting the corneal cells (human) and retinal pigment endothelial cells (rat) against damaging effects of HOand glycosylated proteins (AGE-BSA) compared to its individual components. A mixture is made up of vitamin A, vitamin C, vitamin E, Lycopene, lutein, marigold flower extract, a saffron extract, pine bark extract, grape seed extract, bilberry extract, lipoic acid, L-Arginine and zinc.

Novel Composition Method Of Using The Same For The Treatment Of Lyme Disease

View page
US Patent:
20160339057, Nov 24, 2016
Filed:
Aug 5, 2016
Appl. No.:
15/229245
Inventors:
MATTHIAS W. RATH - APTOS CA, US
Aleksandra Niedzwiecki - APTOS CA, US
Anna Goc - SANJOSE CA, US
International Classification:
A61K 33/18
A61K 31/231
A61K 31/375
A61K 31/216
A61K 31/352
A61K 36/87
A61K 31/593
A61K 31/22
Abstract:
Lyme disease caused by and has been traditionally treated with antibiotics. However, to eradicate all three morphological forms of species such as spirochetes, rounded bodies and biofilm more effective and safe treatment plan is required. In the instant application, Vitamins and Phytobiologicals have been tested for as a short term and long term treatment in vitro and on biofilm. The combination of tested compounds in form of Mix AO seems to be very beneficial in treating Lyme disease caused by and

Novel Composition Method Of Using The Same For The Treatment Of Lyme Disease

View page
US Patent:
20160106777, Apr 21, 2016
Filed:
Oct 19, 2014
Appl. No.:
14/517887
Inventors:
Matthias W. Rath - Aptos CA, US
Aleksandra Niedzwiecki - APTOS CA, US
Anna Goc - San Jose CA, US
International Classification:
A61K 33/18
A61K 31/201
A61K 31/23
A61K 31/353
A61K 31/216
A61K 31/375
A61K 31/51
A61K 31/525
A61K 31/455
A61K 31/191
A61K 31/4415
A61K 31/4188
A61K 31/519
A61K 31/714
A61K 31/593
Abstract:
A composition for treating Lyme disease caused by Species, comprising a vitamin, a small fatty acid signaling molecule, an essential amino acid, a flavonoid, a plant extract and a mineral.
Anna A Goc from San Jose, CA, age ~48 Get Report